GSDME and esophageal squamous cell carcinoma: Inhibition of PLK1 by BI2536 treatment in esophageal squamous cell carcinoma (ESCC) induced pyroptosis both in vitro and in vivo through the BAX/caspase-3/GSDME pathway and boosted the sensitivity to cisplatin (113).